Navigation Links
Resverlogix Presenting at Biotech Showcase
Date:1/11/2010

TSX Exchange Symbol: RVX

Also participating at 28th Annual JP Morgan Healthcare conference

SAN FRANCISCO, CA and CALGARY, Jan. 11 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that Donald J. McCaffrey will be presenting at the Biotech Showcase 2010 conference on Tuesday, January 12, 2009 at the Marines' Memorial Club and Hotel in San Francisco, California.

Biotech Showcase provides presenting companies an opportunity to present to an audience of investors and biopharmaceutical executives during the course of the industry's largest annual healthcare investor conference. In conjunction with this presentation Resverlogix will also be participating in the annual JP Morgan Healthcare conference, which is a separate event that is taking place at the Sir Francis Drake Hotel also in San Francisco.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with future financings, the success of research and development programs. Additionally, risks and uncertainties are discussed in detail in the October 31, 2009 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
2. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
3. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
4. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
5. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
6. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
7. Resverlogix Provides Quarterly Update
8. Resverlogix Board of Directors Update
9. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
10. Resverlogix Announces Closing of Debt Redemption
11. Resverlogix Eliminates Sixty Percent of Remaining Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... David Nolte, PhD accepted Purdue University’s 2016 ... Research Park of West Lafayette, Indiana. , The top commercialization award is ... success with, commercializing discoveries from Purdue research. “This award is truly an honor. ...
(Date:2/23/2017)... FRANCISCO , Feb. 23, 2017   ViaCyte, ... Type 1, a not-for-profit advocacy and education group for ... grant from Beyond Type 1 to support ViaCyte,s efforts ... other insulin-requiring diabetes.  For more than ... cell replacement therapies with a focus on the treatment ...
(Date:2/22/2017)... 2017  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Annual Biocom Global Life Science Partnering Conference.  The presentation ... at the Torrey Pines Lodge, in San Diego.  ... Biocom who have chosen our company, amongst numerous others, ... investors, and clinical researchers," said Mr. Chen. "In contrast ...
(Date:2/22/2017)... ... ... LabRoots , the leading provider of educational and interactive virtual events ... the launch of a new scholarship for young scientists seeking a degree in any ... open to all high school seniors, 17 years or older; as well as those ...
Breaking Biology Technology:
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
Breaking Biology News(10 mins):